Literature DB >> 34762269

Inhibition of Proliferation in Ovarian Cancer Cell Line (PA-1) by the Action of Green Compound "Betanin".

Rakshanaa R1, Mohiraa Shafreen1, Nitin Kumar2.   

Abstract

Ovarian carcinoma has a cure rate of 30% which makes it deadlier than any other disease. There are a number of genetic and epigenetic changes that lead to ovarian carcinoma cell transformation. Chemoprevention of cancer through application of natural compounds is the need of present generation as other methods are rigorous and have many side effects. Betanin, a compound from Beta vulgaris extract is used in present study to check its potential for inhibition of (PA-1) cancer cell proliferation. Determination of IC50 values through MTT assay was carried out, in addition measurement of mitochondrial membrane potential (MMP), effect of reactive oxygen species (ROS) generation, and induction of apoptosis in ovarian cancer cells through betanin was also observed. Results have shown betanin as a potential candidate for inhibition of ovarian cancer cell proliferation and it can be taken up as a serious compound for further studies for its application in cancer cure.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Apoptosis; Betanin; MTT assay; Mitochondrial membrane potential; Ovarian cancer; Reactive oxygen species

Mesh:

Substances:

Year:  2021        PMID: 34762269     DOI: 10.1007/s12010-021-03744-0

Source DB:  PubMed          Journal:  Appl Biochem Biotechnol        ISSN: 0273-2289            Impact factor:   2.926


  35 in total

Review 1.  A systematic overview of chemotherapy effects in ovarian cancer.

Authors:  T Högberg; B Glimelius; P Nygren
Journal:  Acta Oncol       Date:  2001       Impact factor: 4.089

2.  Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

Authors:  Jacobus Pfisterer; Marie Plante; Ignace Vergote; Andreas du Bois; Hal Hirte; Angel J Lacave; Uwe Wagner; Anne Stähle; Gavin Stuart; Rainer Kimmig; Sigrid Olbricht; Tien Le; Janusz Emerich; Walther Kuhn; James Bentley; Christian Jackisch; Hans-Joachim Lück; Justine Rochon; Annamaria Hayden Zimmermann; Elizabeth Eisenhauer
Journal:  J Clin Oncol       Date:  2006-09-11       Impact factor: 44.544

3.  Dietary compounds galangin and myricetin suppress ovarian cancer cell angiogenesis.

Authors:  Haizhi Huang; Allen Y Chen; Yon Rojanasakul; Xingqian Ye; Gary O Rankin; Yi Charlie Chen
Journal:  J Funct Foods       Date:  2015-05-01       Impact factor: 4.451

4.  Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

Authors:  J P Neijt; S A Engelholm; M K Tuxen; P G Sorensen; M Hansen; C Sessa; C A de Swart; F R Hirsch; B Lund; H C van Houwelingen
Journal:  J Clin Oncol       Date:  2000-09       Impact factor: 44.544

5.  Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.

Authors:  Gabriella Ferrandina; Manuela Ludovisi; Domenica Lorusso; Sandro Pignata; Enrico Breda; Antonella Savarese; Pietro Del Medico; Laura Scaltriti; Dionyssios Katsaros; Domenico Priolo; Giovanni Scambia
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544

6.  Isolation and characterization of a new compound from Prunus mume fruit that inhibits cancer cells.

Authors:  Jong Tae Jeong; Jae-Hak Moon; Keun-Hyung Park; Chul Soo Shin
Journal:  J Agric Food Chem       Date:  2006-03-22       Impact factor: 5.279

7.  Betanin a betacyanin pigment purified from fruits of Opuntia ficus-indica induces apoptosis in human chronic myeloid leukemia Cell line-K562.

Authors:  Devalraju Sreekanth; M K Arunasree; Karnati R Roy; T Chandramohan Reddy; Gorla V Reddy; Pallu Reddanna
Journal:  Phytomedicine       Date:  2007-05-07       Impact factor: 5.340

8.  Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.

Authors:  Jalid Sehouli; O Camara; M Schmidt; S Mahner; G Seipelt; B Otremba; B Schmalfeldt; H Tesch; C Lorenz-Schlüter; G Oskay-Ozcelik
Journal:  Cancer Chemother Pharmacol       Date:  2009-01-21       Impact factor: 3.333

9.  Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group.

Authors:  K Aabo; M Adams; P Adnitt; D S Alberts; A Athanazziou; V Barley; D R Bell; U Bianchi; G Bolis; M F Brady; H S Brodovsky; H Bruckner; M Buyse; R Canetta; V Chylak; C J Cohen; N Colombo; P F Conte; D Crowther; J H Edmonson; C Gennatas; E Gilbey; M Gore; D Guthrie; B Y Yeap
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

Review 10.  p53-Based cyclotherapy: exploiting the 'guardian of the genome' to protect normal cells from cytotoxic therapy.

Authors:  B Rao; S Lain; A M Thompson
Journal:  Br J Cancer       Date:  2013-11-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.